NSP vs. NBIX

In the year-to-date period, NSP achieves a -15.93% return, which is significantly lower than NBIX's -9.88% return. Both investments have delivered pretty close results over the past 10 years, with NSP having a 11.59% annualized return and NBIX not far behind at 11.25%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Insperity, Inc. (NSP) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NSP Sharpe Ratio is -0.71, which is lower than the NBIX Sharpe Ratio of -0.24. The chart below compares the historical Sharpe Ratios of NSP and NBIX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NSP's dividend yield for the trailing twelve months is around 3.71%, while NBIX has not paid dividends to shareholders.

The maximum NSP drawdown since its inception was -95.37%, roughly equal to the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for NSP and NBIX.

The current volatility for Insperity, Inc. (NSP) is 9.65%, while Neurocrine Biosciences, Inc. (NBIX) has a volatility of 11.54%. This indicates that NSP experiences smaller price fluctuations and is considered to be less risky than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Insperity, Inc. and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.